6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-04-17), Mind Medicine's 6-1 Month Momentum % is -2.16%.
The industry rank for Mind Medicine's 6-1 Month Momentum % or its related term are showing as below:
MNMD's 6-1 Month Momentum % is ranked better than 64.04% of 1474
companies
in the Biotechnology industry
Industry Median: -13.84
vs MNMD: -2.16
Competitive Comparison of Mind Medicine's 6-1 Month Momentum %
For the Biotechnology subindustry, Mind Medicine's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mind Medicine's 6-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mind Medicine's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Mind Medicine's 6-1 Month Momentum % falls into.
Mind Medicine (NAS:MNMD) 6-1 Month Momentum % Calculation
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum %
=
( Price 1-month ago
/
Price 6-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mind Medicine (NAS:MNMD) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Mind Medicine 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Mind Medicine's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MNMD has been successfully added to your